Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORTE BIOSCIENCES, INC.

(FBRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Forte Biosciences : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis

05/14/2021 | 09:21am EDT


ę MT Newswires 2021
All news about FORTE BIOSCIENCES, INC.
06/04FORTE BIOSCIENCES, INC.á : Change in Directors or Principal Officers, Submission..
AQ
05/14FORTE BIOSCIENCESá : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says ..
MT
05/12FORTE BIOSCIENCESá : ANNOUNCES FIRST QUARTER 2021 RESULTS AND PROVIDES A GENERAL..
PU
05/10FORTE BIOSCIENCES, INC. á : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
05/10FORTE BIOSCIENCES, INC.á : Financial Statements and Exhibits, Regulation FD Disc..
AQ
05/10FORTE BIOSCIENCES, INC.á : Announces First Quarter 2021 Results and Provides a G..
BU
05/03FORTE BIOSCIENCES, INC.á : to Announce First Quarter 2021 Results and Provide a ..
BU
03/26FORTE BIOSCIENCESá : Citigroup Starts Forte Biosciences at Buy With $75 Price Ta..
MT
03/24FORTE BIOSCIENCESá : Q4 Loss Narrows Amid Higher Spending
MT
03/24FORTE BIOSCIENCES, INC.á : Announces 4Q and Full Year 2020 Results and Provides ..
BU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -22,6 M - -
Net Debt 2021 96,0 M - -
P/E ratio 2021 -25,2x
Yield 2021 -
Capitalization 538 M 538 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 9
Free-Float 72,3%
Chart FORTE BIOSCIENCES, INC.
Duration : Period :
Forte Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORTE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 86,00 $
Last Close Price 39,83 $
Spread / Highest target 164%
Spread / Average Target 116%
Spread / Lowest Target 75,7%
EPS Revisions
Managers and Directors
NameTitle
Paul A. Wagner Chairman, President & Chief Executive Officer
Anthony A. Riley Chief Financial Officer
Daniel J. Burge Chief Medical Officer & Head-Clinical Development
Lawrence F. Eichenfield Independent Director
Steven Andrew Kornfeld Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FORTE BIOSCIENCES, INC.9.39%538
GILEAD SCIENCES, INC.16.87%85 397
WUXI APPTEC CO., LTD.28.23%65 765
REGENERON PHARMACEUTICALS9.19%54 626
BIONTECH SE167.63%52 693
VERTEX PHARMACEUTICALS-20.04%48 918